Tag:

Shire

Latest Headlines

Latest Headlines

Solo Shire moves 500 to Boston as it pushes ahead with reorg

More than 500 Pennsylvania-based Shire workers are shipping up to Boston in a move CEO Flemming Ornskov says will "streamline operations and drive further efficiencies."

Shire orders 500-plus staffers to move to Boston-area biotech 'Mecca'

Shire is following the biopharma trend of ditching far-flung outposts in favor of a centralized hub, shifting workers from its former U.S. headquarters in Pennsylvania to its Boston-area home base in a move the company believes will better align its sprawling business.

Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal

AbbVie can count this among the consequences of canceling its Shire buyout: Deal-focused hedge funds are losing investors.

Shire CEO happy to fly solo again after AbbVie deal's collapse

Post-Shire-breakup, AbbVie CEO Richard Gonzalez says his company will be scouting about for other "strategic" M&A hookups. But Shire chief Flemming Ornskov isn't interested in courting another buyer.

Billionaire Singer threatens to sue AbbVie over Shire breakup

A $1.64 billion breakup fee may have placated buyout target Shire after AbbVie pulled the plug on their $55 billion agreement. But investors? At least one may still be planning a little ax-grinding.  

Shire poised to succeed as solo act post-AbbVie with solid Q3 earnings

Shire is riding solo after AbbVie called it quits on its proposed $52 billion acquisition, but the company isn't shedding too many tears. The Dublin-based drugmaker announced third-quarter earnings that beat analysts' expectations, leaving the door open for success post-AbbVie.

Top investor bails on Valeant bid, backing Allergan-Shire combo instead

Valeant's takeover partner, Bill Ackman, is not slowing down in his pursuit to land a deal for Allergan. But a key investor may no longer be quite so gung-ho.

AbbVie faces stumbling blocks after cutting cord on $55B Shire deal

Days after AbbVie recommended that shareholders vote against its proposed $55 billion deal for Shire, the company officially cut the cord and terminated its pending merger. And while Shire has big plans to succeed solo, AbbVie could face a few stumbling blocks without the Dublin-based company by its side.

AbbVie's $55B deal for Shire is officially dead. Now what?

Shire and AbbVie have formally called it quits on a planned $55 billion merger, leaving each company to get by on the merits of its own pipeline and talk up the benefits of life without the other.

Left at the altar by AbbVie, Shire has cash, options and an M&A pedigree

While its merger with AbbVie is looking dead, Shire is likely in line for a $1.6 billion breakup fee, cash that could fund a major M&A push. And with renowned dealmakers in its executive ranks, Shire may not be lonely for long.